Masakazu Hatano

895 total citations
42 papers, 561 citations indexed

About

Masakazu Hatano is a scholar working on Psychiatry and Mental health, Pharmacology and Biological Psychiatry. According to data from OpenAlex, Masakazu Hatano has authored 42 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Psychiatry and Mental health, 15 papers in Pharmacology and 7 papers in Biological Psychiatry. Recurrent topics in Masakazu Hatano's work include Schizophrenia research and treatment (16 papers), Bipolar Disorder and Treatment (13 papers) and Treatment of Major Depression (13 papers). Masakazu Hatano is often cited by papers focused on Schizophrenia research and treatment (16 papers), Bipolar Disorder and Treatment (13 papers) and Treatment of Major Depression (13 papers). Masakazu Hatano collaborates with scholars based in Japan, United States and Germany. Masakazu Hatano's co-authors include Nakao Iwata, Taro Kishi, Kenji Sakuma, Yuki Matsuda, Makoto Okuya, Toshikazu Ikuta, Shigeki Yamada, Yasuyuki Ogata, Kazuhisa Sekimizu and Toshio Kubota and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and British Journal of Cancer.

In The Last Decade

Masakazu Hatano

39 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masakazu Hatano Japan 11 190 161 92 81 66 42 561
D. C. Rao United States 15 187 1.0× 119 0.7× 242 2.6× 55 0.7× 23 0.3× 29 751
Rhiannon V. McNeill Germany 15 189 1.0× 123 0.8× 32 0.3× 14 0.2× 90 1.4× 26 546
Gabriella Marcon Italy 18 114 0.6× 382 2.4× 48 0.5× 72 0.9× 43 0.7× 40 850
Éva Kereszturi Hungary 15 127 0.7× 220 1.4× 135 1.5× 16 0.2× 126 1.9× 35 913
Yijie Du China 15 93 0.5× 159 1.0× 50 0.5× 16 0.2× 84 1.3× 37 661
Jung-Eun Choi South Korea 14 130 0.7× 89 0.6× 71 0.8× 20 0.2× 30 0.5× 27 509
Fernando Brivio Italy 17 136 0.7× 106 0.7× 50 0.5× 15 0.2× 176 2.7× 34 702
Barbara Steinborn Poland 15 303 1.6× 164 1.0× 63 0.7× 32 0.4× 35 0.5× 74 650
Guoqing Zhao China 12 120 0.6× 93 0.6× 28 0.3× 51 0.6× 13 0.2× 30 478
Donna Simcoe United States 7 51 0.3× 64 0.4× 59 0.6× 63 0.8× 32 0.5× 7 530

Countries citing papers authored by Masakazu Hatano

Since Specialization
Citations

This map shows the geographic impact of Masakazu Hatano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masakazu Hatano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masakazu Hatano more than expected).

Fields of papers citing papers by Masakazu Hatano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masakazu Hatano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masakazu Hatano. The network helps show where Masakazu Hatano may publish in the future.

Co-authorship network of co-authors of Masakazu Hatano

This figure shows the co-authorship network connecting the top 25 collaborators of Masakazu Hatano. A scholar is included among the top collaborators of Masakazu Hatano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masakazu Hatano. Masakazu Hatano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kishi, Taro, Toshikazu Ikuta, Leslie Citrome, et al.. (2025). Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Translational Psychiatry. 15(1). 211–211. 2 indexed citations
2.
Hatano, Masakazu, et al.. (2025). Estimating the incidence of actionable drug-gene interactions in Japanese patients with major depressive disorder. Frontiers in Psychiatry. 16. 1542000–1542000. 2 indexed citations
3.
Hatano, Masakazu, et al.. (2024). A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis. Clinical Psychopharmacology and Neuroscience. 22(3). 442–450. 3 indexed citations
4.
Kishi, Taro, Kenji Sakuma, Masakazu Hatano, et al.. (2024). Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta‐analysis. Neuropsychopharmacology Reports. 44(1). 267–271. 1 indexed citations
5.
Kishi, Taro, Toshikazu Ikuta, Kenji Sakuma, et al.. (2024). Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis. Molecular Psychiatry. 29(12). 3893–3899. 11 indexed citations
6.
Kishi, Taro, Kenji Sakuma, Masakazu Hatano, Makoto Okuya, & Nakao Iwata. (2023). Early relapse after antidepressant discontinuation may represent antidepressant discontinuation syndrome in major depressive disorder: A meta-analysis. Asian Journal of Psychiatry. 82. 103502–103502. 2 indexed citations
7.
Hatano, Masakazu, et al.. (2023). Effectiveness of Clozapine on Employment Outcomes in Treatment-Resistant Schizophrenia: A Retrospective Bidirectional Mirror-Image Study. Neuropsychiatric Disease and Treatment. Volume 19. 615–622. 3 indexed citations
8.
Hatano, Masakazu, et al.. (2023). Analysis of clozapine-induced seizures using the Japanese Adverse Drug Event Report database. PLoS ONE. 18(6). e0287122–e0287122. 10 indexed citations
9.
10.
Sakuma, Kenji, Taro Kishi, Ikuo Nomura, et al.. (2023). Phosphodiesterase type 5 inhibitors for the treatment of sexual dysfunction in males with major depressive disorder: A systematic review and meta‐analysis. Psychiatry and Clinical Neurosciences. 77(5). 297–299.
11.
Kishi, Taro, Toshikazu Ikuta, Kenji Sakuma, et al.. (2023). Safety profile of antidepressant for Japanese adults with major depressive disorder: A systematic review and network meta‐analysis. Psychiatry and Clinical Neurosciences. 78(2). 142–144. 1 indexed citations
12.
Kishi, Taro, Kenji Sakuma, Masakazu Hatano, et al.. (2023). Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis. Neuropsychopharmacology Reports. 44(1). 216–220. 1 indexed citations
13.
Kishi, Taro, Toshikazu Ikuta, Kenji Sakuma, et al.. (2022). Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular Psychiatry. 28(1). 402–409. 71 indexed citations
14.
Kishi, Taro, Kenji Sakuma, Masakazu Hatano, & Nakao Iwata. (2022). N‐acetylcysteine for schizophrenia: A systematic review and meta‐analysis. Psychiatry and Clinical Neurosciences. 77(2). 119–121. 5 indexed citations
15.
Kishi, Taro, Kenji Sakuma, Masakazu Hatano, et al.. (2022). Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression. Molecular Psychiatry. 28(3). 974–976. 10 indexed citations
16.
Hatano, Masakazu, et al.. (2021). Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study. Neuropsychiatric Disease and Treatment. Volume 17. 3655–3661. 5 indexed citations
17.
Hatano, Masakazu, et al.. (2021). Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan. Clinical Psychopharmacology and Neuroscience. 19(4). 610–617. 3 indexed citations
18.
Kishi, Taro, Kenji Sakuma, Makoto Okuya, Masakazu Hatano, & Nakao Iwata. (2021). Duration of long‐acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia. Psychiatry and Clinical Neurosciences. 75(7). 240–241. 1 indexed citations
19.
Kamei, Hiroyuki, et al.. (2020). Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia. Clinical Psychopharmacology and Neuroscience. 18(1). 49–57. 9 indexed citations
20.
Kamei, Hiroyuki, et al.. (2020). Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series. Clinical Psychopharmacology and Neuroscience. 18(1). 159–163. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. C. Rao Breakdown of academic impact, for papers by Rhiannon V. McNeill Breakdown of academic impact, for papers by Gabriella Marcon Breakdown of academic impact, for papers by Éva Kereszturi Breakdown of academic impact, for papers by Yijie Du Breakdown of academic impact, for papers by Jung-Eun Choi Breakdown of academic impact, for papers by Fernando Brivio Breakdown of academic impact, for papers by Barbara Steinborn Breakdown of academic impact, for papers by Guoqing Zhao Breakdown of academic impact, for papers by Donna Simcoe
Rankless by CCL
2026